Rexgenero has announced that Huw Jones has joined the company’s board as a non-executive director, and will chair the company’s remuneration committee. This follows the recent appointment of David Horn Solomon as chairman of Rexgenero’s Board.
Huw is currently CEO of Chronos Therapeutics Limited (Chronos), a spin out from the University of Oxford, UK, focused on the development of a therapies for behavioural brain diseases. He has completed a transformation of Chronos, including extracting the company from the university, restructuring the organisation and completing the acquisition of an early brain disease development portfolio from Shire PLC (now part of Takeda). Huw was recently voted European CEO of the Year, Drug Discovery by print and online publication European CEO Magazine, alongside industry leaders from companies such as Adidas, Unilever and Spotify in their respective sectors.
Solomon comments: “Huw brings a huge amount of commercial, development and leadership experience from many senior industry roles. He joins Rexgenero as we ramp up recruitment for our Phase III SALAMANDER trials of REX-001 in patients with chronic limb-threatening ischaemia and start planning for the next stage of our growth and development.”
Jones adds: “The promise of cell and gene therapies has long been recognised. I believe that Rexgenero’s deep understanding of this fast-moving and exciting area, together with a late-stage clinical asset targeting a large global patient population positions it well for future success. I look forward to helping Rexgenero achieve this.”
Rexgenero is a privately held, UK-based regenerative medicine company pioneering the development of patient-specific cell-based therapies to treat serious diseases such as chronic limb-threatening ischaemia. Its lead product, REX-001, consists of a suspension of immune and progenitor cells involved in immune modulation, blood vessel regeneration and remodelling and improvement in blood flow. It is manufactured using a patient’s own cells, avoiding undesired immune responses.